Targeting CDK‐2 With Novel Indole‐Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies
Drug Development Research · 2026
DOI: 10.1002/ddr.70357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Wagdy M Eldehna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Indoles, Cyclin-Dependent Kinase 2, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: King Saud University (ORF-2026-344)..
Abstract (Originalsprache)
The current study devised and synthesized a novel class of pyrazole derivatives based on indole as possible inhibitors of cyclin‐dependent kinase‐2 (CDK‐2). 1 H NMR, 13 C NMR, NOESY, HMQC, and elemental analysis were used to confirm the structural integrity of the synthesized compounds. Promising CDK‐2 inhibitory activity was observed in biological assays, and numerous compounds exhibited sub‐micromolar IC 50 values. Compound 5 d outperformed the reference inhibitor Roscovitine (IC 50 = 0.716 µM) as the most potent inhibitor (IC 50 = 0.536 µM), followed by compound 9 g (IC 50 = 0.675 µM). SAR analysis showed that the observed activity was significantly influenced by the electronic nature of the added substituents as well as the orientation of the indole bond, with brominated derivatives exhibiting greater potency. The antiproliferative activity of the most potent compounds against the cancer cell lines HepG2, HCT‐116, and MCF‐7 was further assessed. In addition to having an enhanced selectivity index for normal MCF‐10A cells (SI = 8.00 vs. 4.96 for Roscovitine), compound 5 d had the greatest activity against MCF‐7 cells (IC 50 = 6.78 µM), surpassing Roscovitine (IC 50 = 8.11 µM). According to mechanistic investigations, compound 5 d significantly reduced the S‐phase population, markedly promoted apoptosis, and caused G1 and G2/M cell‐cycle arrest. Additionally, the consistent binding of compound 5 d within the ATP‐binding pocket of CDK‐2 was confirmed by molecular docking and molecular dynamics simulations, and attractive drug‐like and pharmacokinetic features, similar to those of Roscovitine, were demonstrated by in silico ADMET predictions. All of these results point to compound 5 d as a promising lead scaffold for developing potent CDK‐2‐targeted anticancer agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
- Scientific Research and Innovation Support Unit, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
- Department of Pharmacology, College of Pharmacy, The Islamic University, Najaf, Iraq.
- Institute of Cancer Therapeutics, University of Bradford, Bradford, UK.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
ORCID-Profile: Wagdy M Eldehna, Zainab M Elsayed, Mohamed R Elnagar, Maha-Hamadien Abdulla, Abdulrahman M Saleh, Abdelrahman R Shalabi, Suliman Alshamari, Mohamed Fares, Haytham O Tawfik
Förderung
- King Saud University (ORF-2026-344).
Zitieren
APA
Eldehna, W. M., Elsayed, Z. M., Elnagar, M. R., Omar, Y. M., Abdulla, M. H., Saleh, A. M., Shalabi, A. R., Elimam, D. M., Alshamari, S., Fares, M., & Tawfik, H. O. (2026). Targeting CDK‐2 With Novel Indole‐Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies. Drug Development Research. https://doi.org/10.1002/ddr.70357
Vancouver
Eldehna WM, Elsayed ZM, Elnagar MR, Omar YM, Abdulla MH, Saleh AM, et al. Targeting CDK‐2 With Novel Indole‐Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies. Drug Development Research. 2026. doi:10.1002/ddr.70357
BibTeX
@article{Eldehna2026,
author = {Eldehna, Wagdy M and Elsayed, Zainab M and Elnagar, Mohamed R and Omar, Yasser M and Abdulla, Maha-Hamadien and Saleh, Abdulrahman M and Shalabi, Abdelrahman R and Elimam, Diaaeldin M and Alshamari, Suliman and Fares, Mohamed and Tawfik, Haytham O},
title = {Targeting CDK‐2 With Novel Indole‐Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70357}
}
EUVIMED